January 10th 2025
The adcomm meeting is expected to happen in the first half of 2025, and means the FDA expects to miss the target PDUFA date.
May 3rd 2024
The sNDA for the brexpiprazole plus sertraline therapy is based on positive phase 2 and 3 clinical trials showing improvement in PTSD-specific scale scores.